Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study.

IF 1.9 Q3 DERMATOLOGY
Indian Dermatology Online Journal Pub Date : 2025-02-27 eCollection Date: 2025-03-01 DOI:10.4103/idoj.idoj_913_23
Farheen Begum, Sasmita Mishra, Ajaya K Jena, Maitreyee Panda
{"title":"Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study.","authors":"Farheen Begum, Sasmita Mishra, Ajaya K Jena, Maitreyee Panda","doi":"10.4103/idoj.idoj_913_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA) is an autoimmune, T-cell-mediated disorder manifesting as non-scarring alopecia. Treatment consists of corticosteroids, calcineurin inhibitors, prostaglandin analogs, minoxidil, anthralin, vitamin D analogs, and JAK STAT inhibitors. Despite several treatment options, personal opinions regarding the safety and efficacy of a particular treatment are highly variable. This has led the management of AA to be quite challenging.</p><p><strong>Aim: </strong>To compare the efficacy and safety between the three molecules, namely mometasone 0.1% ointment, calcipotriol 0.005% ointment, and tacrolimus 0.1% ointment, in localized AA.</p><p><strong>Patients and methods: </strong>Patients were randomized into three groups, and topical medications were dispensed for each group in unlabeled tubes. Lesional photographs, dermoscopic images, Severity of Alopecia Tool (SALT) scoring, hair pull test, and Dermatology Life Quality Index questionnaires were done at the baseline visit and at every follow-up visit at 4 weeks and 8 weeks from the baseline visit.</p><p><strong>Results: </strong>At the end of 8 weeks, both mometasone and calcipotriol groups had a significant decrease in their SALT scores (<0.001), but the tacrolimus group did not show any significant change in parameters at the end of the study.</p><p><strong>Limitations: </strong>The main drawback is that there was no control group and the vehicle dispensed was ointment formulation, which may have penetration issues. The lack of long-term follow-up is also a limitation of this study.</p><p><strong>Conclusion: </strong>Both mometasone and calcipotriol formulations were found to be effective in the treatment of localized stable AA; however, calcipotriol preparation was associated with minimal side effects.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"16 2","pages":"248-257"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Dermatology Online Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/idoj.idoj_913_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Alopecia areata (AA) is an autoimmune, T-cell-mediated disorder manifesting as non-scarring alopecia. Treatment consists of corticosteroids, calcineurin inhibitors, prostaglandin analogs, minoxidil, anthralin, vitamin D analogs, and JAK STAT inhibitors. Despite several treatment options, personal opinions regarding the safety and efficacy of a particular treatment are highly variable. This has led the management of AA to be quite challenging.

Aim: To compare the efficacy and safety between the three molecules, namely mometasone 0.1% ointment, calcipotriol 0.005% ointment, and tacrolimus 0.1% ointment, in localized AA.

Patients and methods: Patients were randomized into three groups, and topical medications were dispensed for each group in unlabeled tubes. Lesional photographs, dermoscopic images, Severity of Alopecia Tool (SALT) scoring, hair pull test, and Dermatology Life Quality Index questionnaires were done at the baseline visit and at every follow-up visit at 4 weeks and 8 weeks from the baseline visit.

Results: At the end of 8 weeks, both mometasone and calcipotriol groups had a significant decrease in their SALT scores (<0.001), but the tacrolimus group did not show any significant change in parameters at the end of the study.

Limitations: The main drawback is that there was no control group and the vehicle dispensed was ointment formulation, which may have penetration issues. The lack of long-term follow-up is also a limitation of this study.

Conclusion: Both mometasone and calcipotriol formulations were found to be effective in the treatment of localized stable AA; however, calcipotriol preparation was associated with minimal side effects.

0.1%莫米松软膏、0.005%钙化三醇软膏和0.1%他克莫司软膏治疗局限性斑秃的安全性和有效性比较:三组随机临床研究
背景:斑秃(AA)是一种自身免疫、t细胞介导的疾病,表现为非瘢痕性脱发。治疗包括皮质类固醇、钙调磷酸酶抑制剂、前列腺素类似物、米诺地尔、炭疽素、维生素D类似物和JAK STAT抑制剂。尽管有几种治疗方案,但关于特定治疗的安全性和有效性的个人意见是高度可变的。这使得AA的管理相当具有挑战性。目的:比较0.1%莫米松软膏、0.005%钙化三醇软膏和0.1%他克莫司软膏治疗局部AA的疗效和安全性。患者和方法:将患者随机分为三组,每组在未标记的试管中给药。在基线就诊时进行病变照片、皮肤镜图像、脱发严重程度工具(SALT)评分、拔毛测试和皮肤病生活质量指数问卷调查,并在基线就诊后4周和8周的每次随访中进行。结果:8周结束时,莫米松组和钙化三醇组患者的SALT评分均有显著下降(局限性:主要缺点是没有对照组,配用的载体为软膏配方,可能存在渗透问题)。缺乏长期随访也是本研究的一个局限性。结论:莫米松和钙化三醇制剂治疗局部稳定性AA均有效;然而,钙化三醇制剂的副作用最小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
11.80%
发文量
201
审稿时长
49 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信